NTRK1 and breast carcinoma: Compelling evidence has demonstrated that several tyrosine kinase receptors, including HER-2[12,13], epithelial growth factor receptor (EGFR)[30,31], and insulin-like growth factor-1 receptor (IGF-1R)[32,33] participate in acquired endocrine resistance in breast cancer.